1-6 of 6
Diego Vieyra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS

Carl Ola Landgren, Ajai Chari, Yael C. Cohen, Andrew Spencer, Peter M Voorhees, Irwindeep Sandhu, Matthew W Jenner, Dean Smith, Michele Cavo, Niels W.C.J. van de Donk, Meral Beksac, Phillippe Moreau, Hartmut Goldschmidt, Diego Vieyra, Linlin Sha, Liang Li, Els Rousseau, Robyn M. Dennis, Robin Carson, Craig C. Hofmeister
Journal: Blood
Blood blood.2024025897.
https://doi.org/10.1182/blood.2024025897
Published: 2024
Includes: Supplemental data
Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau
Journal: Blood
Blood (2024) 144 (Supplement 1): 4757.1.
https://doi.org/10.1182/blood-2024-199752
Published: 2024
Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Luca Bertamini, Cathelijne Fokkema, Paula Rodríguez-Otero, Mark van Duin, Niels W.C.J. Van De Donk, Mattia D'Agostino, Evangelos Terpos, Diego Vieyra, Ricardo M. Attar, Anna Sitthi-Amorn, Robin Carson, Michel Delforge, Christoph Driessen, Roman Hajek, Mario Boccadoro, Hermann Einsele, Annette Vangsted, Vincent H.J. Van Der Velden, Fredrik Schjesvold, Artur Jurczyszyn, Meral Beksac, Andrew Spencer, Annemiek Broijl, Tom Cupedo, Philippe Moreau, Pieter Sonneveld
Journal: Blood
Blood (2024) 144 (Supplement 1): 487.
https://doi.org/10.1182/blood-2024-199550
Published: 2024
Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez Otero, Joan Bladé, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 2): LBA-1.
https://doi.org/10.1182/blood-2023-191911
Published: 2023
Journal Articles

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Yaël C. Cohen, Philippe Moreau, Jaszianne Tolbert, Xiang Qin, Xuewen Ma, Diego Vieyra, Angelique Langlois, Christelle Courtoux, William Terry, Lixia Pei, Christoph Heuck, Peter Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 4418–4419.
https://doi.org/10.1182/blood-2022-162733
Published: 2022
Journal Articles

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Christie P.M. Verkleij, Kristine A. Frerichs, Carolien Duetz, Sonja Zweegman, Paola M. Homan-Weert, Monique C. Minnema, Annemiek Broyl, Mark-David Levin, Gerard M.J. Bos, Marie José Kersten, Saskia K. Klein, Medya M. Shikhagaie, Maria Krevvata, Tineke Casneuf, Yann Abraham, Raluca I. Verona, Tina Smets, Greet Vanhoof, Diana Cortes-Selva, Laure van Steenbergen, Diego Vieyra, Pieter Sonneveld, Tuna Mutis, Niels W.C.J. van de Donk
Journal: Blood
Blood (2021) 138 (Supplement 1): 728.
https://doi.org/10.1182/blood-2021-150913
Published: 2021